Company Overview of OncoCyte Corporation
OncoCyte Corporation develops genetically modified stem cells for finding malignant tumors while carrying genes that cause the destruction of the cancer cells. It offers PanC-Dx bladder cancer markers to the performance of cystoscopy. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation operates as a subsidiary of BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502
Founded in 2009
Key Executives for OncoCyte Corporation
Chief Executive Officer of Biotime,Inc. and President of Biotime,Inc.
Compensation as of Fiscal Year 2014.
OncoCyte Corporation Key Developments
BioTime, Inc. and OncoCyte Corporation Announces Initial Data from Ongoing Clinical Study of Collagen Type X as A Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers
Apr 20 15
BioTime, Inc. and OncoCyte Corporation announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx™, OncoCyte’s non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The controlled study, initiated at Scottsdale Medical Imaging Laboratories in Scottsdale, AZ, is ongoing and has nearly completed enrollment of over 600 patients. The goal of this study is to assess the performance of PanC-Dx™ in discriminating patients with malignant breast lesions from those with negative findings or benign findings. Study investigators are collecting blood samples from patients undergoing screening or diagnostic mammography. Patient blood samples are being assessed for levels of OncoCyte’s PanC-Dx™ markers, including the concentration of the protein COL10A1, using proprietary assays and the results are compared to radiological and pathology findings. Expression of the gene COL10A1 at an mRNA level has been shown in past studies to be significantly elevated in multiple and diverse malignant tumor types including cancers of the breast, stomach, colon, lung, bladder, pancreas, and ovaries. In addition, the protein was shown to be specifically localized within tumor vasculature. Early data showed that PanC-Dx™ identified a mean concentration of COL10A1 protein in sera of breast cancer patients (n=33) that was 35% higher than the mean COL10A1 value in sera of normal individuals (n=32). No significant differences were noted when comparing breast cancer patients to patients with confirmed benign disease suggesting that additional biomarkers may be necessary to discriminate these two populations. Based on this data, PanC-Dx™ offered improved performance as compared to the commercially available enzyme-linked immunosorbent assay (ELISA) manufactured with polyclonal antibodies that study investigators previously used in analyzing over 400 serum samples from healthy volunteers and cancer patients. Evaluation of the performance of PanC-Dx™ demonstrated 86% area-under-the-curve (AUC) of the Receiver Operating Characteristic (ROC) curve, which determines the level of specificity and sensitivity of the product. The polyclonal ELISA demonstrated 74% AUC of the ROC curve.
BioTime, Inc. and Oncocyte Corporation Announce Positive Clinical Results of Panc-Dx, Oncocyte’s Class of Proprietary, Non-Invasive Cancer Diagnostic Tests, in Detecting the Most Common Type of Bladder Cancer, Urothelial Carcinoma
Apr 20 15
BioTime, Inc. and its subsidiary OncoCyte Corporation announced positive clinical results of PanC-Dx, OncoCyte’s class of proprietary, non-invasive cancer diagnostic tests, in detecting the most common type of bladder cancer, urothelial carcinoma. The first clinical study was conducted by OncoCyte in collaboration with investigators in the Department of Pathology at Johns Hopkins University School of Medicine led by Matthew T. Olson, M.D., Assistant Professor and Associate Director of the Division of Cytopathology in the Department of Pathology at Johns Hopkins University School of Medicine and principal investigator of the trial, and Dorothy Rosenthal, M.D., Professor of Pathology, Oncology and Gynecology/Obstetrics at Johns Hopkins University School of Medicine and collaborator on the study. Clinical investigation involved collection of 90 urine samples from patients undergoing urine cytology for the diagnosis of either primary or recurrent bladder cancer. Patient urine samples were assessed microscopically for the presence of cancer cells using the current standard-of-care method of cytopathology; in parallel, study investigators analyzed the urine samples for gene expression. Study investigators then investigated the performance the 43-marker panel derived from the first clinical study using a set of 195 urine samples obtained from a second, large ongoing clinical study at multiple urology clinics in the United States. Investigators in the trial are collecting urine samples from patients undergoing cystoscopy for the diagnosis of either primary or recurrent bladder cancer.
OncoCyte Corporation Announces Availability of Abstracts with New Clinical Data from Studies of PanC-Dx™ Cancer Diagnostic in Bladder and Breast Cancer
Mar 20 15
BioTime Inc. and its subsidiary OncoCyte Corporation announced the online availability of abstracts providing human clinical data highlighting the potential of PanC-Dx™, OncoCyte’s class of non-invasive cancer diagnostics based on OncoCyte’s proprietary set of cancer markers. These markers were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. These markers, including COL10A1, are the subject of multiple pending patent claims filed in numerous countries worldwide and are owned by OncoCyte. Data included in the abstracts will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015. The first abstract describes the clinical data and assay development progress of OncoCyte’s bladder cancer diagnostic test. Data obtained from a clinical study recently completed in collaboration with investigators in the Department of Pathology at Johns Hopkins University School of Medicine, was to assess the performance of OncoCyte’s proprietary diagnostic technology in detecting the most common type of bladder cancer, urothelial carcinoma (UC). Study investigators collected 90 urine samples from patients undergoing urine cytology for the diagnosis of either primary or recurrent bladder cancer. An analysis was performed and a panel of markers that discriminates UC from non-cancerous conditions was identified. Evaluation of the performance of this gene panel indicated high levels of sensitivity and specificity (Receiver Operating Characteristic area under the curve of greater than 0.9). Additional evaluation of this gene panel in the context of a larger multi-site study is ongoing and results from this expanded clinical study will be included in the presentation. The second presentation will provide a summary of the clinical data and assay development progress of OncoCyte’s breast cancer diagnostic test. Specifically, the abstract describes the potential utility of COL10A1 as a blood-based biomarker for multiple cancers, including breast cancer. This study involving over 600 patients is being conducted at Scottsdale Medical Imaging Laboratories.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|